Med. praxi. 2026;23(4):228-234 | DOI: 10.36290/med.2026.032

Patient with rheumatic disease in primary care

MUDr. Jana Tomasová Studýnková, Ph.D.
Revmatologický ústav, Praha a Revmatologická klinika 1. LF UK v Praze

Musculoskeletal symptoms are among the most common problems encountered in general practice. Although most cases are of mechanical origin, a significant proportion of patients have inflammatory rheumatic or systemic autoimmune diseases, in which early diagnosis has a major impact on prognosis. The role of the general practitioner is to recognize features suggestive of an inflammatory etiology and to initiate an appropriate diagnostic work-up. The cornerstone of differential diagnosis is the distinction between mechanical and inflammatory causes of symptoms based on medical history, physical examination, and appropriately indicated laboratory and imaging investigations. Early recognition of rheumatic disease relies particularly on clinical features such as morning stiffness lasting > 30 minutes, pain at rest or during the night, joint swelling, and extra-articular manifestations, which may precede abnormalities in laboratory and imaging findings. In primary care, early suspicion and prompt referral to a rheumatologist are crucial. Only early therapeutic intervention within the so-called "window of opportunity" can prevent irreversible damage and significantly improve long-term prognosis and patients' quality of life.

Keywords: patient with rheumatic disease in primary care, inflammatory rheumatic diseases, systemic autoimmune diseases, early diagnosis, differential diagnosis.

Received: June 26, 2026; Revised: August 11, 2026; Accepted: August 12, 2026; Published: October 14, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomasová Studýnková J. Patient with rheumatic disease in primary care. Med. praxi. 2026;23(4):228-234. doi: 10.36290/med.2026.032.
Download citation

References

  1. Němec P. Revmatoidní artritida - diagnostika a léčba. Med praxi. 2023;20(4):201-210. Go to original source...
  2. Inchingolo F, Inchingolo AM, Fatone MC, et al. Management of rheumatoid arthritis in primary care: a scoping review. Int J Environ Res Public Health. 2024 May 22;21(6):662. Go to original source...
  3. Němec P. Revmatoidní artritida - klinické vyšetření a diferenciální diagnostika. Med. praxi. 2023;20(2):88-94. Go to original source...
  4. Brown P, Pratt AG, Hyrich KL. Therapeutic advances in rheumatoid arthritis. BMJ. 2024 Jan 17;384:e070856. Go to original source...
  5. Šenolt L, Mann H, Závada J, et al. Revmatoidní artritida: doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. SVL ČLS JEP; 2021.
  6. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. PMID: 37827694. Go to original source...
  7. Šenolt L, Mann H, Tomčík M, et al. Česká revmatologická společnost ČLS JEP. Doporučení pro farmakologickou léčbu revmatoidní artritidy - aktualizace 2024. Česká revmatologie. 2024.
  8. Kharouf F, Gladman DD. Advances in the management of psoriatic arthritis in adults. BMJ. 2024 Nov 21;387:e081860. doi: 10.1136/bmj-2024-081860. PMID: 39572047. Go to original source... Go to PubMed...
  9. Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016 Jul 7;2:16047. doi: 10.1038/nrdp.2016.47. PMID: 27383445. Go to original source... Go to PubMed...
  10. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9. PMID: 28413064. Go to original source...
  11. Day J, Crawshaw H, Lim KW, et al. An Update on Vasculitis for the General Physician. Br J Hosp Med (Lond). 2025 Mar 26;86(3):1-21. doi: 10.12968/hmed.2024.0435. Epub 2025 Mar 25. PMID: 40135305. Go to original source... Go to PubMed...
  12. Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017 Jul;17(4):322-328. doi: 10.7861/clinmedicine.17-4-322. PMID: 28765407; PMCID: PMC6297649. Go to original source... Go to PubMed...
  13. Danve A, Alexander S, Afinogenova Y, et al. Early diagnosis of axial spondyloarthritis among patients with chronic back pain using a clinical screening tool and referral strategy. Rheumatol Adv Pract. 2025 Jul 28;9(3):rkaf086. doi: 10.1093/rap/rkaf086. PMID: 40901640; PMCID: PMC12401578. Go to original source... Go to PubMed...
  14. van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-65-74. Epub 2014 Oct 30. PMID: 25365092.
  15. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10. Erratum in: Ann Rheum Dis. 2023 Mar;82(3):e76. doi: 10.1136/ard-2022-223356corr1. PMID: 36357155. Go to original source...
  16. van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537-3546. doi: 10.1002/art.27692. Go to original source... Go to PubMed...
  17. Mandl P, Navarro-Compán V, Terslev L, et al; European League Against Rheumatism (EULAR). EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis. 2015 Jul;74(7):1327-39. doi: 10.1136/annrheumdis-2014-206971. Epub 2015 Apr 2. PMID: 25837448. Go to original source... Go to PubMed...
  18. van den Bosch WB, Mangnus L, Reijnierse M, et al. The diagnostic accuracy of the squeeze test to identify arthritis: a cross-sectional cohort study. Ann Rheum Dis. 2015 Oct;74(10):1886-9. doi: 10.1136/annrheumdis-2014-207202. Epub 2015 Apr 24. PMID: 25911456. Go to original source... Go to PubMed...
  19. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004 Jul;43(7):906-14. doi: 10.1093/rheumatology/keh199. Epub 2004 Apr 27. PMID: 15113999. Go to original source...
  20. Stack RJ, Shaw K, Mallen C, et al. Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature. Ann Rheum Dis. 2012 Apr;71(4):493-7. doi: 10.1136/ard.2011.155416. Epub 2011 Nov 25. PMID: 22121128. Go to original source... Go to PubMed...
  21. Teixeira RL, da Silva Vieira R, Saavedra MJ, et al. Structured and prompt treatment of early arthritis in clinical practice leverages window of opportunity and leads to excellent clinical outcomes: an innovative retrospective cohort study. Clin Rheumatol. 2024 Dec;43(12):3941-3950. doi: 10.1007/s10067-024-07192-z. Epub 2024 Oct 29. PMID: 39472411; PMCID: PMC11582134. Go to original source...
  22. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022 Jun;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733. Epub 2022 Feb 2. PMID: 35110331. Go to original source... Go to PubMed...
  23. Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023 Dec;75(12):2088-2102. doi: 10.1002/art.42646. Epub 2023 Oct 16. PMID: 37845798. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.